Enfusion, Inc. (NYSE:ENFN) COO Sells $31,788.12 in Stock

Enfusion, Inc. (NYSE:ENFN) COO Neal Pawar sold 2,769 shares of the firm’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $11.48, for a total value of $31,788.12. Following the completion of the sale, the chief operating officer now directly owns 1,231,627 shares of the company’s stock, valued at approximately $14,139,077.96. This trade represents a 0.22 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Neal Pawar also recently made the following trade(s):

• On Wednesday, March 5th, Neal Pawar sold 14,560 shares of Enfusion stock. The stock was sold at an average price of $11.38, for a total value of $165,692.80.
• On Wednesday, March 5th, Neal Pawar sold 14,560 shares of Enfusion stock. The stock was sold at an average price of $11.38, for a total value of $165,692.80.

Enfusion Trading Down 0.5 %

ENFN opened at $11.24 on Friday. Enfusion, Inc. has a 1 year low of $7.83 and a 1 year high of $11.80. The stock has a fifty day moving average price of $10.98 and a 200 day moving average price of $9.88. The stock has a market cap of $1.44 billion, a price-to-earnings ratio of 280.95, a PEG ratio of 1.85 and a beta of 0.95.

Enfusion (NYSE:ENFN) last announced its quarterly earnings results on Monday, March 3rd. The company reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). Enfusion had a return on equity of 6.67% and a net margin of 1.70%. The company had revenue of $52.94 million during the quarter, compared to analyst estimates of $53.98 million. As a group, sell-side analysts forecast that Enfusion, Inc. will post 0.06 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on ENFN shares. Piper Sandler raised their target price on Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a research report on Monday, December 23rd. Stifel Nicolaus lifted their price objective on Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. Finally, William Blair reissued a “market perform” rating on shares of Enfusion in a research report on Monday, January 13th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $11.13.

Institutional Trading of Enfusion

A number of institutional investors and hedge funds have recently made changes to their positions in ENFN. KLP Kapitalforvaltning AS acquired a new stake in shares of Enfusion in the fourth quarter worth about $75,000. Harbor Capital Advisors Inc. lifted its position in shares of Enfusion by 12.4% in the third quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock worth $113,000 after buying an additional 1,315 shares during the last quarter. Belvedere Trading LLC acquired a new stake in shares of Enfusion in the third quarter worth about $114,000. Millennium Management LLC acquired a new stake in shares of Enfusion in the fourth quarter worth about $114,000. Finally, Dark Forest Capital Management LP acquired a new stake in shares of Enfusion in the fourth quarter worth about $128,000. Institutional investors and hedge funds own 81.05% of the company’s stock.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.